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anemia (5.4%), coronary atherosclerosis (4.5%), and congestive heart failure (3.5%).
Similarly, the most commonly prescribed medications among CKD patients were 
furosemide (16.3), atorvastatin (9.1%), lisinopril (9.0%), amlodipine (9%), aspirin
(8.6%), levothyroxine (7.9%), metaraminol (7.8%), insulin (7.4), atenolol (6.1%),
and potassium replacement solutions (5.3%). CONCLUSIONS: Our study identiﬁ es
the most common co-morbidities diagnosed among CKD patients. Early screening and 
treatment for these conditions may help lower the rate of progression of CKD.
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IMPACTS OF THE PREVENTIVE TREATMENT OF PATIENTS SUFFERING
FROM RECURRING CYSTITIS BY MEANS OF A STANDARD DRY
CRANBERRY EXTRACT
Taieb C
Pierre Fabre, Boulogne, France
OBJECTIVES: Assess the impacts of the preventive treatment of patients suffering
from recurring cystitis by means of a standard dry cranberry extract. METHODS: An
observational, longitudinal and prospective assessment by Urologists as part of their 
professional everyday activity. RESULTS: Ninety-two female patients, with an average 
age of 53.9–18.9 years, were included in the study. These patients had been monitored
for a period of 7 months (median). Before inclusion, 89 of the patients (96.7%) had
been offered an antibiotherapy. Depending on the patients, the factors that triggered 
their cystitis most frequently were: sexual relations (58.0%), alcohol consumption 
(27.6%) and diarrhoea (19.3%). The frequency and urgency of urination, the burning
sensation upon urination, the inability to completely empty the bladder and sensation 
of heaviness in the pubic region were the ﬁ ve symptoms assessed every three weeks. 
On inclusion, the scores for each symptom were, respectively: 6.2; 6.5; 6.1; 3.1 and
4.6. The overall score was 28.9. After 3 months, the scores for each symptom were, 
respectively: 1.6; 1.9; 1.9; 0.4 and 0.7. The overall score was 7.1. The evolution of 
the overall score (p  0.001) was signiﬁ cant, as was that of each respective symptom.
The prevalence of cystitis at 3 months was 47.6% (versus 96.7%) on inclusion. 
CONCLUSIONS: The prevalence of urinary problems in subjects suffering from
recurring cystitis was halved after 3 months of treatment by means of a standard dry
cranberry extract (96.7% versus 47.6%).
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CASE STUDY OF CREATING A FORMULARY MANAGEMENT PROCESS
AT A COMPREHENSIVE CANCER CENTER IN BANGALORE, INDIA
Hariharaputhran D1, Ajai Kumar B1, Lal LS2
1Bangalore Institute of Oncology, HCG Enterprises Ltd, Bangalore, Karnataka, India, 
2University of Texas MD Anderson Cancer Center, Houston, TX, USA
ORGANIZATION: Bangalore Institute of Oncology (BIO). PROBLEM OR ISSUE 
ADDRESSED: Pharmacy and Therapeutics committee’s responsibilities consist
of developing policies and frameworks to develop an effective formulary taking 
into account both efﬁ cacy and cost considerations. In the Indian pharmaceutical 
environment, multiple manufactures compete for market share, within a single institu-
tion itself, creating inefﬁ ciencies in inventory management and the overall pharma-
ceutical budget. GOALS: The purpose of this project was to create a formulary for 
the Bangalore Institute of Oncology (BIO), taking into account both cost and efﬁ cacy 
considerations, while still maintaining physician preferences and autonomy. A prelimi-
nary ABC analysis, also known as a Pareto analysis, was conducted to identify items 
which have a signiﬁ cant impact on the overall inventory costs and well as, identify
and rank areas for improvement and management interventions. OUTCOMES 
ITEMS USED IN THE DECISION: The institutional ABC analysis was conducted for
the period of October 2006 to September 2007. Pharmaceutical items were valued 
(item cost multiplied by quantity issued/consumed in period) with the results subse-
quently ranked. IMPLEMENTATION STRATEGY: The total pharmacy budget for 
the ﬁ scal year was 15.89 Crore Rupees (Rs) (3.96 million US dollars, based on 40:1
exchange rate) with a resulting margin of 3.51 Crore Rupees (Rs) ($877,500), which 
consisted of 1033 different products from 247 manufacturers. The ABC analysis
revealed that 48 medications made up 85% of the total budget, with bortezomib being
the highest oncology contributor and meropenem being the highest non-oncology 
contributor. Analysis of purchases within the 35 oncology products revealed that there
were 29 manufacturers with 95 different brands, and for the 13 non oncology prod-
ucts, there were 14 manufacturers with 20 different brands. Based on this analysis,
consolidation of drug products and drug manufacturers were considered as an inter-
vention for formulary management by the Pharmacy and Therapeutics Committee. 
Three different options were considered by the committee. Option 1 consolidates to
only a single brand based on the highest margin, which would improve the present 
margin by 46% from 3.51 Crore Rs ($877,500) to 5.15 Crore Rs ($1,287,500).
Option 2 consolidates to having two brands, one from the preferred vendor with the 
highest margin and the other from the innovator/premium vendor, which would
improve the margin by 36% to 4.76 Crore Rs ($1,119,000). Option 3 consolidates 
to three brands: the preferred vendor with the highest margin, the lowest cost brand 
from the patient’s perspective, and the innovator/premium vendor brand, which would 
improve the margin by 24% to 4.36 Crore Rs ($1,090,000). Option 3 was chosen as
the basis for creating the institutional formulary, due to physician ﬂ exibility, patient
affordability, and improvements to the margin. RESULTS: The pharmaceutical 
company Dr. Reddy was selected as the preferred vendor for the creation of the for-
mulary and Option 3 was applied to all of the following pharmaceuticals(N): mono-
clonal antibodies(6); oral chemotherapy(23); intravenous chemotherapy(31); hormonal 
agents (9); and supportive care agents(13), for a total of 82 separate chemical entities.
Of the total 82 chemical entities, 43 (52.4%) have one brand available, 29 (35.4%) 
have two brands available, and 10 (12.2%) have three brands available. The preferred
vendor was utilized for 18 of these products. If the same total quantity is purchased 
again in 2008, the total purchase cost will be 54.15 Crore Rs ($13,538,047) with a 
resulting margin of 20.13 Crore Rs ($5,033,454). LESSONS LEARNED: Consolida-
tion of the pharmaceutical products and creation of a formulary results in higher than 
expected margin, even when the same purchase quantity is applied. Market competi-
tion forces appear to work better in an environment of a closed formulary system.
PCASE2
THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION
REGARDING CHARACTERISTICS OF HEALTH CARE USERS
Figueira CMG, Serrano E, Sena E
Vila Velha Hospital, Vila Velha, Espirito Santo, Brazil
ORGANIZATION Vila Velha Hospital (VVH). Vila Velha, Espirito Santo, Brazil. 
PROBLEM OR ISSUE ADDRESSED To assure client space and ﬁ delity in the market 
of health services through novel strategies able to supply health care providers 
with information about their clients and service costs at hospitals in the metropolitan
region of Vitoria-ES, Brazil. GOALS 1-Semestral increase of 30% in the number of 
clients referred for consultation at VVH and their ﬁ delity as a result of the good quality 
of services. 2-Semestral increase of 20% in VVH services required from health care
providers. OUTCOMES ITEMS USED IN THE DECISION Data from a search 
regarding the opinion of clients and health care providers about the ideal health ser-
vices were considered in the ﬁ nal decision. This information was obtained from 
PROAHSA (Program of Advanced Studies in Hospital Administration and Health
Systems) and from CHQ (Program of Quality Control of Medical Services). IMPLE-
MENTATION STRATEGY Analysis of patient stay at the hospital and its total cost,
considering age, site and disease of the client at VVH. All diseases described in ICD 
(International Classiﬁ cation of Diseases) were classiﬁ ed in acute, chronic and acciden-
tal, according to the duration of disease, loss of function, treatment type and length, 
and recurrence probability. RESULTS The data obtained allowed the comprehension
of characteristics of clients seen at VVH, and also allowed the proper estimation of 
treatment costs for various pathologies and the development of a cost curve per
pacient, materials and medications. LESSONS LEARNED The understanding of client 
speciﬁ cities allows price negotiation in a more secure and transparent way for both 
the hospital and the health care providers, and allows a more efﬁ cient handling of 
ﬁ nancial resources.
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HTA PROCEDURES IN DRUG REIMBURSEMENT PROCESS IN POLAND. 
EVOLUTION OF RECOGNITION THE ROLE OF AGENCY OF HEALTH
TECHNOLOGY ASSESSMENT (AHTAPOL) BY POLICY MAKERS
Krol ZJ, Matusewicz W, Musialowicz A
Agency for Health Technology Assessment, Warsaw, Poland
ORGANIZATION: Agency of Health Technology Assessment Warsaw, Poland.
PROBLEM OR ISSUE ADDRESSED: Need to supply safe and most effective drugs, 
services and devices for publicly insured inhabitants through different mechanisms of 
spending public sources. GOALS: (1) Development a health technology assessment
procedures and incorporating its results into decision-making process of using public 
sources in Polish Health Care System. (2) Setting priorities of assessing areas – accord-
ing to health beneﬁ ts ﬁ nanced from public means reimbursement criteria. (3) Providing 
sufﬁ cient information for making decisions. OUTCOMES ITEMS USED IN THE
DECISION: There were different measurements performed during planning, imple-
menting and revising process of development AHTAPol. Measures were elaborated
parallel by national and international experts. IMPLEMENTATION STRATEGY:
AHTAPol was establish on 2006 as a governmental organization whose aims are:
assessment of medical procedures – health technologies; elaboration, veriﬁ cation, 
gathering and dissemination of information about HTA results of such assessments,
methodology and support of guidelines development made based on them; elaboration 
of recommendations for the Minister of Health concerning ﬁ nancing health technolo-
gies from public means (the role of the Consultative Council); collaboration with other 
authorities and organization acting in health care system and performing other duties
delegated by the Minister of Health (MoH) of Poland. One of the ﬁ rst actions of 
AHTAPol was related to delegation of MoH for development the basic beneﬁ t 
package. For the estimation of budget needed to services included into beneﬁ t package 
the costs calculating program was designed and pilot activities were performed. 
And ﬁ nally drug dossiers assessment and appraisal process led to recommendation 
for decision of MoH. These actions were supported by development department 
focused on analytical part and independent body – Consultative Council acting as an
appraisal committee RESULTS: Involvement of AHTAPol in activities related to based 
beneﬁ t package were limited to development of central medical services (with descrip-
tion of diagnoses and professional specialties) data-base. Costs calculation of these 
services was not started. Engagement of nationally recognized experts supported by
AHTAPol ended on development national cost calculating project. This project most 
probably will start in 2009. The most expected by policy-makers, public and clinicians 
activities of AHTAPol nowadays is involvement on the process of drug and modern 
medical technology reimbursement by elaboration of recommendations for decision 
of MoH. Organizational respond of AHTAPol resulted at the number of recommenda-
tion: 13 in 2007 and 81 in 2008. In 2009 is planed over 300. LESSONS LEARNED:
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There are many lessons speciﬁ cally related to Polish situation (middle sized – 38 mln
inhabitants -European country) but among them some examples can be shared. Settle-
ment organization related to HTA development and support it in self-governed elabo-
rating of assessment and appraisal procedure is one of most important example in our 
opinion. Another is related to international collaboration and many dimensions of it
such as exchanging experience, consulting ideas, sharing knowledge or support in 
training staff.
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THE EVALUATION PROCESS OF A REGIONAL DRUG AND
THERAPEUTIC COMMITTEE IN ITALY: THE EXAMPLE OF NEW
INDICATIONS FOR BEVACIZUMAB
Scroccaro G1, Venturini F2, Alberti C2, Visentin E2, Berardo F2, Paccagnella A3
1Azienda Ospedaliera di Verona, Verona, Italy, 2Veneto Regional Drug Information Center, 
Verona, Italy, 3ULSS 12 Veneziana, Venezia, Italy
ORGANIZATION: The Pharmacy and Therapeutic Committee of the Veneto Region,
Italy, is a regulating body responsible for the deﬁ nition of the Regional Hospital For-
mulary in Veneto. Veneto comprised a territory of 4.800.000 inhabitants in the north-
east part of Italy. The Unit for the Evaluation of Drug Efﬁ cacy (Unità di Valutazione 
dell’Efﬁ cacia del Farmaco, UVEF) is the technical group responsible for the evaluation 
reports of new drugs to be submitted to the Committee. The Committee evaluates the
introduction of new technologies based on relevant information from the literature 
regarding: efﬁ cacy, safety and cost. Cost data are based on the acquisition cost of the 
new drugs and the alternatives already included in the formulary. The HTA reports 
contain the following relevant sections: general information; alternative treatments 
and insights from existing guidelines; efﬁ cacy and safety data; other HTA reports;
pharmacoeconomics data from the literature; comparative drug costs. PROBLEM OR 
ISSUE ADDRESSED: In 2008, four new indications for bevacizumab were approved 
by the National Drug Agency: 1) metastatic colon-rectal cancer in association with 
ﬂ uoropirimidines; 2) in combination with interferon alfa-2a for the ﬁ rst line treatment 
of patients with advanced and/or metastatic renal cell cancer; 3) in combination with 
paclitaxel as ﬁ rst line treatment in metastatic breast cancer; 4) in addition to platinum-
based chemotherapy for the ﬁ rst-line treatment of patients with unresectable advanced, 
metastatic or recurrent non-small-cell lung cancer (other than predominantly squa-
mous cell histology). Due to rising cost for oncological drugs in the region (total 
expenditure for 2007 Euro 151.001.736), the Committee put particular attention to 
the introduction of new oncological drugs in the formulary. GOALS: as in all the 
evaluations made by the committee, the goal was to perform an evaluation process 
taking into account all the relevant information on efﬁ cacy, safety and costs data, in 
order to include in the formulary the indications with a favourable beneﬁ t/risk and 
beneﬁ t/cost proﬁ le. OUTCOMES ITEMS USED IN THE DECISION: The following 
information were part of the evaluation: efﬁ cacy data from main clinical trials (phase 
II and III), published in full and reported in the EMEA assessment report; safety data
from the same sources; considerations on safety, efﬁ cacy and cost by the main regula-
tory and HTA agencies in Europe (e.g., Scottish Medicine Consortium, NICE, HAS 
France); relevant organizational and cost issues arising from published pharmacoeco-
nomic studies, when applicable; comparative drug costs in relation with alternatives
already present in the regional formulary. IMPLEMENTATION STRATEGY: based 
on the produced evaluations, the following were the considerations that brought to 
the Committee’s decisions: 1) metastatic colon-rectal cancer: efﬁ cacy data on second-
line treatment demonstrate a signiﬁ cant improvement in median overall and disease 
free survival; efﬁ cacy data on ﬁ rst-line treatment were less robust, with an increase in 
disease free survival of one month. In the last case the Committee did not include the
drug in the formulary 2) renal cancer: the Committee considered the unfavourable 
safety proﬁ le of the drug, the less accepted route of administration (ev instead than 
oral sunitinib in ﬁ rst line treatment and sorafenib in second line), the need of a con-
comitant administration of interferon; the higher cost of the new regimen. Based on 
these factors, the Committee did not include the new indication in the formulary 3) 
breast cancer: based on the efﬁ cacy data, which demonstrated almost a double pro-
gression free survival, and a strict correlation between progression free survival and 
overall survival, the Committee approved the indication 4) non small cell lung cancer:
the Commission analized the efﬁ cacy data and pointed out that the positive results 
were obtained in association with carboplatin and paclitaxel. The indication was
included in the formulary with a limitation in association with these two drugs.
RESULTS: these decisions have been implemented and hospitals in the region are
actually using the drug according to the restrictions. In parallel, a national registry by 
the Italian Regulatory Agency on Drugs had been set up. From the registry, it will be 
possible to perform a qualitative analysis on the usage, and on the indications and 
patient’s outcomes. LESSONS LEARNED: In the evaluation process, the decision is
mainly taken based on the results on efﬁ cacy and safety from the published clinical
trials. Other countries regulatory agencies opinions are considered, while published 
cost effectiveness data conducted in different settings are often useless for taking deci-
sions at local level, due to lack of transferability of the chosen models and/or the dif-
ferent cost and organizational data.
